KeepTel-AM Tablet contains a combination of Telmisartan 40 mg and Amlodipine 5 mg, indicated for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduced blood pressure. Amlodipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and decreased systemic vascular resistance. The combined effect of these agents provides complementary mechanisms to achieve effective blood pressure control, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. KeepTel-AM is particularly beneficial for patients inadequately controlled on monotherapy or those requiring multiple antihypertensive agents. It should be administered once daily, with or without food, as prescribed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and monitoring of blood pressure and electrolyte levels is recommended during therapy. Common side effects may include dizziness, peripheral edema, and headache. This combination therapy enhances patient compliance by reducing pill burden while maintaining efficacy and safety in hypertension management.